Figure 2From: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programmeTime to occurrence of primary composite CV event with linagliptin versus total comparator.Back to article page